InsidersTradesSigma
Follow the 漢田生技 stock price and the full directors' dealings record of the company, a publicly traded company based in Taiwan. Shares trade on the TW market, under the supervision of TWSE / TPEx (MOPS). Market capitalisation: €2bn. The latest transaction was reported on 17 June 2026 (Negotiated). Among the most active insiders: 曾士哲. All data is accessible without an account.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
漢田生技 is a company listed on the XTAI market, specializing in the biotechnology sector. It focuses on developing innovative solutions in the healthcare field.